Clinical trials: Small Lymphocytic Leukemia
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The risk of immunosuppression deters many patients from receiving fludarabine, while combination chemotherapy regimens are poorly tolerated by elderly or infirm chronic lymphocytic leukemia (CLL) patients.
- Trial name
- NCT01113632
- Testing
- Ofatumumab
- Where
- 13 sites in United States
- Volunteers
- 77 people
- Sponsor
- SCRI Development Innovations, LLC
Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL)
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Background: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are cancers often treated with the drug ibrutinib. For some people, ibrutinib stops working.
- Trial name
- NCT04209621
- Testing
- Duvelisib, Ibrutinib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Lymphocytic Leukemia(CLL), Small Lymphocytic Lymphoma
Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL
To determine the response to the combination of Revlimid (Lenalidomide)+ Vidaza (Azacitidine) in patients with relapsed/refractory CLL and SLL Hypothesis- lenalidomide's activity in combination with azacitidine may further…
- Trial name
- VZCLLPI0146 (NCT01241786)
- Testing
- Revlimid, Azacitidine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Hackensack Meridian Health
Lymphoid Leukemia, Non-Hodgkin's Lymphoma
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This trial studies how well bendamustine and rituximab in combination with copanlisib work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Conditions
- Lymphoid Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT04155840
- Testing
- Copanlisib, Rituximab, Bendamustine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Washington
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT01027000
- Testing
- rituximab, busulfan, cyclophosphamide
- Where
- 25 sites in United States
- Volunteers
- 68 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
The primary objective of this study is to evaluate the 28-day safety and tolerability, and to determine the pharmacokinetics (PK) of idelalisib in Japanese participants with relapsed or refractory indolent B-cell non-Hodgkin…
- Conditions
- Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT02242045
- Testing
- Idelalisib
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Gilead Sciences
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients
The purpose of the study is to investigate whether the combination of rituximab and high dose methylprednisolone can be given together, can reduce the amount of cancer cells that are present prior to starting venetoclax, and…
- Trial name
- NCT04981912
- Testing
- HDMP + rituximab as a means of debulking prior to initiating venetoclax.
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Diego
Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR20A in adult subjects with r/r B-cell NHL or r/r…
- Conditions
- Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory, Chronic Lymphocytic Leukemia
- Trial name
- NCT04030195
- Testing
- PBCAR20A, Fludarabine, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Precision BioSciences, Inc.
Acute Leukemias, Burkitt's Lymphoma
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen.
- Conditions
- Acute Leukemias, Burkitt's Lymphoma, Chronic Myelogenous Leukemia
- Trial name
- NCT02145039
- Testing
- Fludarabine, Cyclophosphamide, Total Body Irradiation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab.
- Trial name
- NCT02384954
- Testing
- Rituximab, N-803
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Altor BioScience
Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This was a single-arm, open-label, multi-center Phase 2 study in participants with histologically documented CLL/SLL who have relapsed after or refractory to ≥ 1 prior treatment regimen(s).
- Trial name
- NCT03206918
- Testing
- Zanubrutinib
- Where
- 11 sites in China
- Volunteers
- 91 people
- Sponsor
- BeiGene
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Growth factors, such as palifermin, may prevent chronic graft-versus-host disease caused by donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01233921
- Testing
- palifermin, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Martin, Paul
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
The standard approach to managing chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) is to wait until you have symptoms before treatment is given.
- Conditions
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Trial name
- NCT03207555
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Chronic Lymphocytic Leukemia
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
This is a multicenter, 2-cohort Phase 2 study assessing both minimal residual disease (MRD)-guided discontinuation and fixed duration therapy with the combination of ibrutinib + venetoclax in subjects with treatment-naïve CLL or…
- Conditions
- Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- Captivate (NCT02910583)
- Testing
- ibrutinib, venetoclax
- Where
- 46 sites in United States, Australia and 4 more
- Volunteers
- 323 people
- Sponsor
- Pharmacyclics LLC.
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
The purpose of this study is to test a combination treatment of acalabrutunib when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) to evaluate if it will be able to improve durable responses and cure some…
- Conditions
- Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Marginal Zone Lymphoma
- Trial name
- NCT04189952
- Testing
- Acalabrutinib, Rituximab, Ifosfamide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Miami
Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
This phase II trial is studying how well giving iodine I 131 tositumomab together with etoposide and cyclophosphamide followed by autologous stem cell transplant works in treating patients with relapsed or refractory…
- Conditions
- Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
- Trial name
- NCT00073918
- Testing
- cyclophosphamide, etoposide, iodine I 131 tositumomab
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Fred Hutchinson Cancer Center
Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
RATIONALE: Biological therapies, such as agatolimod sodium, may stimulate the immune system in different ways and stop cancer cells from growing.
- Conditions
- Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00438880
- Testing
- Agatolimod Sodium, Indium In-111 Ibritumomab Tiuxetan, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
This is a pilot phase 2 study investigating the safety and efficacy of ibrutinib combined with short-course fludarabine in previously untreated CLL patients.
- Trial name
- NCT02514083
- Testing
- Ibrutinib, Fludarabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
This phase II trial studies how well an umbilical cord blood transplant with added sugar works with chemotherapy and radiation therapy in treating patients with leukemia or lymphoma.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03096782
- Testing
- Anti-Thymocyte Globulin, Busulfan, Clofarabine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, representing approximately 30% of all adult leukemias.
- Trial name
- NCT05105841
- Testing
- Venetoclax, Ibrutinib, Obinutuzumab
- Where
- 20 sites in Japan
- Volunteers
- 20 people
- Sponsor
- AbbVie